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Introduction
First described in 2002, osteonecrosis of
the jaw (ONJ, or avascular necrosis of the
jaw) is an uncommon but potentially
serious side eﬀect of treatment with
bisphosphonates. Although
typically identified in patients with
multiple myeloma and other
malignancies, a few cases have been
reported in patients taking
bisphosphonates - a potent drug class
used in the treatment of osteoclastmediated bone resorption issues,
including postmenopausal osteoporosis,
Paget's disease, multiple myeloma, and
malignant hypercalcemia. The clinical
diagnosis of ONJ can be obscured by
jaw pain, abscess, swelling, and fistulas,
but exposed bone is a distinctive
sign. This reports a case of ONJ
secondary to bisphosphonate use in a
65-year-old woman and clinical
management complications.

Case Presentation
A 65-year-old lady with history of agerelated osteoporosis and compression
fractures on alendronate for 4
years, squamous cell carcinoma of neck
status post excision and radiotherapy 11years prior, Sjogren's syndrome and
discoid lupus on hydroxychloroquine,
diabetes, hypertension, stroke and
multiple dental abscesses presents with
persistent neck pain. Initial CT neck with
contrast showed diﬀuse fat stranding.
Subsequently, alendronate was
discontinued due to jaw necrosis
suspicion. Eight months later, repeat CT
scan showed new non-mass-like soft
tissue thickening in the subcutaneous fat
abutting the right anterior mandible
with mandibular teeth cavities and
periapical lucencies, likely to be
periodontal cellulitis
versus radiation osteonecrosis.

Tennessee State University, Department of Internal Medicine

Case presentation continued
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Later, patient complained of a piece of
bone penetrating the skin of her chin and
presented with continuous drainage from
sinus tract in her mandible, which was
diagnosed as osteonecrosis attributed to
bisphosphonates, previous radiation
therapy, and dental abscesses.

Discussion continued
Case reports and series suggest benefit
from hyperbaric oxygen therapy in wound
healing, pain, and quality of life at three
months, however no significant
diﬀerences exist with outcomes beyond
three months. Patients being considered
for therapy with a bisphosphonate should
be thoroughly evaluated for dental issues,
prior to initiating therapy. Conservative
management with limited debridement,
antibiotic therapy as needed, and topical
mouth rinses rather than aggressive
surgical resection are recommended.
Conservative therapy may result in
healing in a significant proportion of
patients. Surgical resection of necrotic
bone should be reserved for refractory or
advanced cases.

Patient was started on abaloparatide, an
osteo-anabolic medication for
osteoporosis and enrolled in hyperbaric
oxygen therapy which immensely helped
in controlling sinus drainage. Patient is
currently awaiting mandibular
reconstruction surgery.

Discussion

Conclusion

ONJ, often associated with pain,
swelling, exposed bone, local infection,
and pathologic fracture of the jaw, is a
rare complication of bisphosphonate
therapy. Currently, no prospective data
exists to advise the benefits of therapy
discontinuation however most clinical
practices tend to discontinue at least
temporarily. The incidence increases
with longer treatment duration,
particularly when therapy exceeds four
years. Risk factors for developing ONJ
while taking bisphosphonates include IV
administration, anticancer therapy, dose
and duration of exposure, dental
extractions/implants, glucocorticoids,
smoking, diabetes, and preexisting dental
disease.

Providers should remain cautious while
prescribing high doses of
bisphosphonates in patients with
increased risk factors to prevent, timely
diagnose and treat this condition.
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